Neurocrine announces settlement of INGREZZA ANDA litigation

Neurocrine Biosciences announced that is has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications, ANDAs, brought by companies seeking approval to market a generic version of INGREZZA prior to the expiration of applicable Neurocrine patents. As part of the resolution of these lawsuits, four companies have the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain customary circumstances. “These settlements reinforce our belief in the strength of the INGREZZA intellectual property estate and provide clarity regarding INGREZZA exclusivity. As an innovation-driven biopharmaceutical company, we will continue to develop treatments for under-addressed diseases and rely on a robust patent system to protect that investment in innovation,” said Darin Lippoldt, Chief Legal Office of Neurocrine Biosciences.